Welcome to our dedicated page for Inovio Pharmaceu news (Ticker: INO), a resource for investors and traders seeking the latest updates and insights on Inovio Pharmaceu stock.
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is a biotechnology company developing DNA medicines for HPV-related diseases, cancer, and infectious diseases. The INO news feed on Stock Titan aggregates company-issued press releases, regulatory updates, and other market-moving disclosures so readers can follow how INOVIO’s DNA medicine programs progress over time.
A major focus of recent INOVIO news is INO-3107, an investigational DNA medicine for adults with recurrent respiratory papillomatosis (RRP), a rare HPV-related disease of the respiratory tract. Updates include completion of a rolling Biologics License Application (BLA), FDA acceptance of the BLA for review under a Standard classification, and discussion of the accelerated approval pathway. News items also highlight clinical data showing reductions in the number of surgeries required by trial participants and long-term durability results from retrospective analyses.
Investors can also find announcements on capital-raising transactions, such as underwritten public offerings of common stock and warrants disclosed in Form 8-K filings and related press releases. INOVIO frequently reports on financial results, including quarterly earnings releases, as well as corporate governance and compensation matters like inducement stock option grants under its Inducement Plan.
Additional coverage includes scientific and clinical milestones, such as publication of Phase 1 proof-of-concept data for DNA-Encoded Monoclonal Antibody (DMAb) technology in Nature Medicine and preclinical progress in DNA-encoded protein (DPROT) programs. Conference participation and investor events are also regular topics. For followers of INO stock, this news page offers a centralized view of the company’s clinical, regulatory, financial, and strategic communications.
INOVIO (NASDAQ: INO) reported its Q4 and full-year 2024 financial results, highlighting significant progress toward its first Biologics License Application (BLA) for INO-3107, targeting recurrent respiratory papillomatosis (RRP). The company resolved manufacturing issues and plans to begin rolling BLA submission in mid-2025.
Key financial metrics for 2024 include:
- Cash position: $94.1M (down from $145.3M in 2023)
- Annual revenue: $218,000 (decreased from $832,000 in 2023)
- Net loss: $107.3M or $3.95 per share (improved from $135.1M in 2023)
- R&D expenses: $75.6M (reduced from $86.7M in 2023)
Clinical highlights include promising durability data showing 50% of RRP patients achieved Complete Response in year 2, and positive interim results from their DNA-encoded monoclonal antibodies (DMAb) COVID-19 trial. The company projects its current cash position will support operations into Q1 2026, with an estimated Q1 2025 operational net cash burn of $27M.
INOVIO (NASDAQ: INO) has announced promising interim results from its ongoing Phase 1 proof-of-concept trial for DNA-encoded Monoclonal Antibodies (DMAbs) targeting COVID-19. The trial demonstrated significant achievements in durability and safety:
Key findings include:
- 100% of participants (24/24) maintained stable DMAb levels through week 72
- No anti-drug antibodies (ADA) detected across ~1,000 blood samples
- Well-tolerated with only mild, temporary injection site reactions
- Expressed DMAbs successfully bound to SARS-CoV-2 Spike protein RBD through week 72
The study, conducted in collaboration with The Wistar Institute, AstraZeneca, and the Perelman School of Medicine at the University of Pennsylvania, represents a potential breakthrough in overcoming traditional monoclonal antibody production challenges. The technology shows promise for treating infectious diseases, cancer, and metabolic disorders through long-term therapeutic protein expression.
INOVIO (NASDAQ:INO), a biotechnology company specializing in DNA medicines for HPV-associated diseases, cancers, and infectious diseases, has scheduled the release of its fourth quarter and year-end 2024 financial results for March 18, 2025, after market close.
The company will host a live conference call and webcast at 4:30 p.m. ET on the same day to discuss the financial results and provide a business update. The webcast will include a Q&A session with analysts and will be available for replay for 90 days through the investor relations section of INOVIO's website.
INOVIO (NASDAQ: INO) announced peer-reviewed data from its Phase 1/2 clinical trial of INO-3107 for treating recurrent respiratory papillomatosis (RRP) in Nature Communications. The trial demonstrated significant clinical benefits, with 81.3% (26/32) of patients requiring fewer surgeries post-treatment compared to the previous year. 28.1% (9/32) of patients achieved Complete Response, requiring no surgical intervention.
The treatment showed strong safety profile with only 41% reporting treatment-related adverse events, mostly mild injection site pain (31%) and fatigue (9%). INO-3107 induced lasting T cell responses specific to HPV-6 and HPV-11, with evidence of immune cells traveling to affected tissues.
INOVIO plans to submit its biologics license application (BLA) in mid-2025, seeking rolling submission and priority review. If approved, INO-3107 would become the first DNA medicine approved in the United States.
INOVIO (NASDAQ:INO) announced that it will present immunological activity data for INO-3107 at the American Association for Cancer Research – Immuno-Oncology Discovery and Innovation in Cancer Immunology conference, scheduled for February 23-26, 2025. The poster presentation will focus on the loss of detectable HPV-6 in Recurrent Respiratory Papillomatosis patients following INO-3107 treatment, specifically highlighting the induction of emergent T cells in patients who showed durable complete clinical response. The abstract will be made available on INOVIO's website after the conference.
INOVIO (NASDAQ: INO), a biotechnology company specializing in DNA medicines for HPV-associated diseases, cancer, and infectious diseases, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference.
The company's President and CEO, Dr. Jacqueline Shea, along with Chief Medical Officer Dr. Michael Sumner, will deliver a presentation on Wednesday, February 12, 2025, from 3:20 to 3:50 PM ET. The management team will also conduct one-on-one meetings with registered investors during the conference.
Interested parties can access the presentation through a webcast available on INOVIO's Investor Relations Events page, with replay access available for 90 days following the presentation.
INOVIO highlighted its anticipated 2025 milestones and 2024 achievements. The company plans to submit a biologics license application (BLA) for INO-3107 by mid-2025 for treating recurrent respiratory papillomatosis (RRP). Key 2024 accomplishments include positive durability data showing 50% of RRP patients achieved complete response requiring no surgery by year two, with 88% maintaining complete response through year two and 63% into year three.
The company expects to initiate a confirmatory trial at 20 U.S. academic centers with approximately 100 patients. INOVIO strengthened its financial position with over $60 million from equity offerings in 2024, reporting $84.4 million in cash and equivalents as of September 2024. The company is also progressing with INO-3112 for HPV-related cancer and other pipeline products including INO-4201 for Ebola and DNA monoclonal antibody programs.
INOVIO Pharmaceuticals (Nasdaq: INO) has announced the pricing of a $30 million public offering, consisting of 10,000,000 shares of common stock and accompanying warrants. The combined offering is priced at $3.00 per share with warrants exercisable at $3.76 per share. The offering, expected to close on December 16, 2024, is being managed by Oppenheimer & Co. Inc. and Citizens JMP as joint book-running managers, with Stephens Inc. as lead manager. The gross proceeds of $30 million are calculated before deducting underwriting discounts, commissions, and offering expenses.
INOVIO Pharmaceuticals (Nasdaq: INO) announced plans for a proposed public offering of common stock and accompanying warrants. The biotechnology company, focused on DNA medicines for HPV-related diseases, cancer, and infectious diseases, will sell all securities in the offering. Oppenheimer & Co. Inc. and Citizens JMP are serving as joint book-running managers, with Stephens Inc. as lead manager.
The offering is subject to market conditions, with no guarantees regarding completion, size, or terms. It will be conducted under a shelf registration statement filed with the SEC on November 9, 2023, and declared effective on January 31, 2024.
INOVIO announced promising data from a retrospective trial of INO-3107 for Recurrent Respiratory Papillomatosis (RRP). The trial showed increased Complete Response rates among patients, rising from 28% at the end of the initial 52-week trial to 50% by year 2 and 54% by year 3. 95% of patients maintained or enhanced their Original Response Rate by year 2, with 86% maintaining improvements into year 3. The durability data will inform re-dosing strategies and support INOVIO's BLA submission planned for mid-2025. No treatment-emergent serious adverse events were identified during the retrospective trial.